Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors.
Trial Status:
Not yet recruiting
|
The trial is testing a potential new treatment for Muscle-invasive Bladder Cancer.
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
The Medical Oncology Clinical Research team, based within the Mater Cancer Care Centre, currently has 22 actively recruiting trials.
This trial is for people with gynaecological cancers whose tumours are potentially treatable with endocrine treatment.
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
The research study is testing a potential new treatment for bladder and urothelial cancer.
The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating your cancer when combined with other cancer drugs, compared to the standard of care for people with breast cancer.
The purpose of this study is to compare the effects, good or bad of an investigational product, inavolisib, when combined with palbociclib and fulvestrant. In this study, you will get either inavolisib or placebo and no one (you, your doctors, or the company sponsoring this study) will know who is receiving inavolisib and who is receiving placebo. This helps to ensure that the results are free from bias.
The research project is testing a potential new treatment for nccRCC, called XL092 in a combination with nivolumab.